Town & Country Bank & Trust CO dba First Bankers Trust CO Grows Position in Johnson & Johnson (NYSE:JNJ)

Town & Country Bank & Trust CO dba First Bankers Trust CO raised its holdings in Johnson & Johnson (NYSE:JNJ) by 3.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,041 shares of the company’s stock after acquiring an additional 1,192 shares during the period. Johnson & Johnson makes up 2.1% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s investment portfolio, making the stock its 12th largest position. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Johnson & Johnson were worth $4,663,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Billeaud Capital Management Inc. raised its holdings in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock valued at $6,130,000 after buying an additional 169 shares in the last quarter. Meeder Asset Management Inc. raised its holdings in shares of Johnson & Johnson by 11.1% during the 2nd quarter. Meeder Asset Management Inc. now owns 109,690 shares of the company’s stock valued at $15,277,000 after buying an additional 10,927 shares in the last quarter. Archford Capital Strategies LLC raised its holdings in shares of Johnson & Johnson by 11.2% during the 2nd quarter. Archford Capital Strategies LLC now owns 21,997 shares of the company’s stock valued at $3,064,000 after buying an additional 2,211 shares in the last quarter. Marino Stram & Associates LLC raised its holdings in shares of Johnson & Johnson by 1.2% during the 2nd quarter. Marino Stram & Associates LLC now owns 32,199 shares of the company’s stock valued at $4,485,000 after buying an additional 380 shares in the last quarter. Finally, Palisades Hudson Asset Management L.P. raised its holdings in shares of Johnson & Johnson by 42.6% during the 2nd quarter. Palisades Hudson Asset Management L.P. now owns 2,241 shares of the company’s stock valued at $312,000 after buying an additional 669 shares in the last quarter. 72.01% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently weighed in on JNJ. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective on the stock in a report on Friday. Bank of America restated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Raymond James reduced their price target on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Credit Suisse Group set a $156.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, Barclays began coverage on Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $151.00.

JNJ traded up $3.53 on Friday, hitting $132.59. 2,519,223 shares of the company were exchanged, compared to its average volume of 6,702,304. The firm has a fifty day simple moving average of $129.92 and a two-hundred day simple moving average of $135.00. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The stock has a market capitalization of $347.95 billion, a PE ratio of 16.21, a price-to-earnings-growth ratio of 2.22 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. Johnson & Johnson’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period last year, the company earned $2.10 EPS. On average, equities analysts expect that Johnson & Johnson will post 8.59 earnings per share for the current year.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Cryptocurrencies

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.